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Cystic fibrosis is the most common autosomal recessive
condition in Caucasians and recurrent infections lead to a
plethora of complications. Repeated courses of high dose
intravenous b-lactam antibiotics, such as piperacillin, are
employed for the treatment of respiratory exacerbations.
Unfortunately, delayed-type hypersensitivity reactions
develop in between 26-50% of treated patients. We have
recently described the cellular immunological processes
that underlie drug-specific response in hypersensitive
patients; however, the involvement of the humoral
immune system has not been studied. The aim of this
study was to quantify piperacillin-specific antibodies in
plasma of hypersensitive and tolerant patients and investi-
gate whether B-cells can be stimulated to secrete antibo-
dies in vitro following drug stimulation. Drug-specific
antibodies were quantified by ELISA using piperacillin-
modified BSA as an antigen. Adducts generated using
different drug-protein ratios were used to measure the
degree of conjugation that elicits an antibody response.
BSA was modified with different b-lactam antibiotics to
define structural specificity. Specificity for the piperacillin
BSA adduct was confirmed by hapten inhibition. Mass
spectrometry was used to characterize the Lys residues
modified with piperacillin. B-cells isolated from PBMC
were cultured with piperacillin for 5 days and IgG secre-
tion and B-cell activation was measured using ELISpot
and flow cytometry (CD19, CD27), respectively. A signifi-
cantly higher level of anti-piperacillin IgG antibody was
detected in plasma of hypersensitive patients when hyper-
sensitive and tolerant patients were compared. Hapten
inhibition ELISA confirmed specificity for the piperacillin
antigenic determinant. Antibody binding was detected
with adducts generated at piperacillin:BSA ratios between
1:1 and 100:1. In contrast, antibody binding was not
detectable with penicillin G, amoxicillin or aztreonam
BSA conjugates. IgG antibody secretion was also detected
from purified B-cells from hypersensitive patients cultured
with soluble piperacillin. Drug treatment was associated
with increased expression of the B-cell activation marker
CD27. These data begin to describe the drug-specific
humoral immune response in piperacillin hypersensitive
patients with cystic fibrosis. Further work is needed to
define the role different antibody subtypes play in the
disease pathogenesis.
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